Tempest Therapeutics Secures $2.0M in Warrant Exercise, Issues New Warrants for Future Dilution

summarizeSummary

Tempest Therapeutics raised $2.0 million by inducing a warrant exercise, but issued new warrants for over 2.3 million shares, signaling a highly dilutive financing to address its critical liquidity needs.

check_boxKey Events

• Warrant Exercise & Proceeds

  A holder exercised 1,172,414 existing warrants for $2.0 million in gross proceeds. The original warrants, issued in November 2025 with an adjusted exercise price of $1.75 (after the 2:1 forward split on 2026-01-30), were exercised at a reduced price of $1.73 per share.

• New Warrant Issuance

  The company issued new unregistered warrants to purchase 2,344,828 shares (200% of the exercised amount) at an exercise price of $1.73 per share. These new warrants require stockholder approval and will expire on May 29, 2028.

• Critical Liquidity

  This capital raise provides essential funds for a company with a 'going concern' warning and recent Nasdaq deficiency notices, extending its cash runway from a reported $1.8 million in Q1 2026.

• Significant Dilution

  The issuance of new warrants represents substantial potential future dilution for existing shareholders, reflecting the company's urgent need for capital. The new warrants are priced at $1.73, above the current stock price of $1.43.

auto_awesomeAnalysis

Tempest Therapeutics, facing a 'going concern' warning and Nasdaq deficiency notices, has secured $2.0 million in immediate liquidity by inducing a warrant holder to exercise existing warrants. While this provides critical cash, the company issued new warrants for 2.34 million shares (200% of the exercised amount) at an exercise price of $1.73, which represents significant potential future dilution for existing shareholders. This transaction is a necessary step to extend the company's cash runway and address its financial challenges, especially as the stock trades near its 52-week low.